The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) is a huge mover today! About 361,402 shares traded hands. Ocular Therapeutix Inc (NASDAQ:OCUL) has declined 23.48% since March 8, 2016 and is downtrending. It has underperformed by 32.80% the S&P500.
The move comes after 5 months negative chart setup for the $171.14 million company. It was reported on Oct, 11 by Barchart.com. We have $5.85 PT which if reached, will make NASDAQ:OCUL worth $17.11M less.
Analysts await Ocular Therapeutix Inc (NASDAQ:OCUL) to report earnings on November, 8. They expect $-0.51 EPS, down 8.51% or $0.04 from last year’s $-0.47 per share. After $-0.46 actual EPS reported by Ocular Therapeutix Inc for the previous quarter, Wall Street now forecasts 10.87% negative EPS growth.
Ocular Therapeutix Inc (NASDAQ:OCUL) Ratings Coverage
Out of 3 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ocular Therapeutix has been the topic of 7 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm earned “Equal-Weight” rating on Friday, October 23 by Morgan Stanley. The stock has “Equal Weight” rating given by Morgan Stanley on Thursday, August 13. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) has “Outperform” rating given on Thursday, August 11 by JMP Securities. Morgan Stanley maintained it with “Overweight” rating and $16 target price in Tuesday, June 7 report. The stock has “Overweight” rating given by Morgan Stanley on Thursday, April 28. Morgan Stanley upgraded the stock to “Overweight” rating in Thursday, February 18 report. Nomura initiated it with “Buy” rating and $46 target price in Wednesday, August 5 report.
According to Zacks Investment Research, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.”
Another recent and important Ocular Therapeutix Inc (NASDAQ:OCUL) news was published by Businesswire.com which published an article titled: “Ocular Therapeutixâ„¢ Announces FDA Acceptance of NDA Filing for DEXTENZAâ„¢ for …” on December 09, 2015.
OCUL Company Profile
Ocular Therapeutix, Inc., incorporated on September 12, 2006, is a biopharmaceutical company. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The Company’s hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.